Hypertension
📧 Sign up to get email alerts when something new happens for Hypertension.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2013-08-12Clinical Trial Update: Epidemiology of Stress and the Metabolic Syndrome
A completed clinical trial update examining the epidemiology of stress in relation to metabolic syndrome and related cardiovascular risk fac…
-
CLINICAL_TRIALS trial_result · 2013-08-08Clinical Trial Update: Drug Interaction and Safety Between Valsartan and Rosuvastatin in Healthy Male Volunteers [Phase 1]
Phase 1 clinical trial by LG Life Sciences evaluates the safety and potential interaction between valsartan and rosuvastatin in healthy male…
-
CLINICAL_TRIALS trial_result · 2013-08-07Clinical Trial Update: Safety and Pharmacokinetics Between Fixed-dose Combination VR 160/20 mg and Co-administration of Diovan® (Valsartan) Film-coated Tablet 160 mg and Crestor® (Rosuvastatin) 20 mg [Phase 1]
Phase 1 study assessing safety and pharmacokinetics of the fixed-dose combination VR 160/20 mg compared with co-administration of valsartan …
-
CLINICAL_TRIALS trial_result · 2013-08-07Clinical Trial Update: Longitudinal Cardiac Outcomes and Body Composition
Virginia Commonwealth University completed a clinical trial evaluating longitudinal cardiac outcomes and body composition in cardiovascular …
-
CLINICAL_TRIALS research · 2013-08-07Clinical Trial Update: Biomarkers of Metabolic Syndrome and Prediabetes
This clinical trial update summarizes biomarkers related to metabolic syndrome and prediabetes, including diabetes mellitus and hypertension…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2013-07-31FDA Approved: AMLODIPINE AND ATORVASTATIN — Supplemental Application (Prasco Laboratories)
The FDA approved a supplemental application for the fixed-dose combination of amlodipine and atorvastatin, with Prasco Laboratories listed a…
-
EMA guidance · 2013-07-31Comments invited on draft revised guideline on medicines for the treatment of hypertension
EMA invites comments on a draft revised guideline for medicines used to treat hypertension, seeking stakeholder input before finalization.
-
CLINICAL_TRIALS trial_result · 2013-07-30Clinical Trial Update: Biochemical and Genetic Markers of Hypertension in Women
A completed clinical trial updating findings on biochemical and genetic markers associated with hypertension in women.
-
FDA approval · 2013-07-29FDA Approved: EDARBI — Supplemental Application (Azurity Pharmaceuticals, Inc.)
The FDA approved a supplemental application for EDARBI (azilsartan medoxomil) submitted by Azurity Pharmaceuticals, Inc.
-
CLINICAL_TRIALS withdrawal · 2013-07-29Clinical Trial Update: The Evaluation of Clevidipine in Patients Requiring ICP Monitoring and IV Antihypertensive Therapy [Phase 4]
A Phase 4 clinical trial evaluating clevidipine for hypertension in patients requiring intracranial pressure monitoring has been withdrawn.
-
FDA approval · 2013-07-25FDA Approved: PROCARDIA XL — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
The FDA approved a supplemental application for Procardia XL (nifedipine) from Pfizer Laboratories Div Pfizer Inc.
-
CLINICAL_TRIALS research · 2013-07-25Clinical Trial Update: Management of Albuminuria in Hypertensive Diabetics
Clinical trial update on managing albuminuria in hypertensive patients with type 2 diabetes; no results or status details are provided.
-
FDA label_change · 2013-07-24FDA Approved: NORVASC — Supplemental Application (Viatris Specialty LLC)
FDA approved a supplemental application for Norvasc (amlodipine besylate) resulting in updates to the product labeling.
-
CLINICAL_TRIALS trial_result · 2013-07-24Clinical Trial Update: Angiotensinogen Gene and Human Hypertension
Completed clinical trial investigating the role of the angiotensinogen gene in human hypertension.
-
CLINICAL_TRIALS research · 2013-07-22Clinical Trial Update: Eplerenone and Aliskiren Research Targeting Hypertensive Patients With Left Ventricular Hypertrophy [Phase 4]
A Phase 4 clinical trial is evaluating the combination of eplerenone and aliskiren in hypertensive patients with left ventricular hypertroph…
-
CLINICAL_TRIALS trial_result · 2013-07-17Clinical Trial Update: Uric Acid and Hypertension in African Americans [Phase 3]
Phase 3 trial update examining the relationship between uric acid and hypertension in African Americans; results posted in 2013.
-
CLINICAL_TRIALS trial_result · 2013-07-15Clinical Trial Update: Ganglionated Plexi Ablation vs Renal Denervation in Patients Undergoing Pulmonary Vein Isolation [Phase 2]
This Phase 2 trial comparing ganglionated plexi ablation to renal denervation in atrial fibrillation patients undergoing pulmonary vein isol…
-
CLINICAL_TRIALS trial_result · 2013-07-10Clinical Trial Update: Combined Treatment of Resistant Hypertension and Atrial Fibrillation [Phase 2]
A Phase 2 trial evaluating a combined treatment approach for resistant hypertension and atrial fibrillation has completed.
-
CLINICAL_TRIALS trial_result · 2013-07-10Clinical Trial Update: Pharmacogenomic Evaluation of Antihypertensive Responses [Phase 4]
Phase 4 pharmacogenomic study evaluating how genetic factors influence individuals' blood pressure responses to antihypertensive medications…
-
FDA approval · 2013-07-09FDA Approved: AMLODIPINE BESYLATE — Supplemental Application (Ascend Laboratories, LLC)
The FDA approved Ascend Laboratories' supplemental application for amlodipine besylate, confirming the approval of the ANDA supplement for t…
-
CLINICAL_TRIALS trial_result · 2013-07-09Clinical Trial Update: Urine Chloride/Creatinine Ratio for Estimation of Urine Sodium
This completed clinical trial investigated whether the urine chloride/creatinine ratio can estimate urine sodium in people with hypertension…
-
CLINICAL_TRIALS research · 2013-07-08Clinical Trial Update: Renal Sympathetic Denervation in Patients With Drug-resistant Hypertension and Symptomatic Atrial Fibrillation [NA]
This entry reports a clinical trial evaluating renal sympathetic denervation for drug-resistant hypertension in patients with symptomatic at…
-
FDA approval · 2013-07-03FDA Approved: BENICAR — Supplemental Application (Cosette Pharmaceuticals, Inc.)
The FDA approved a supplemental application for Benicar (olmesartan medoxomil) submitted by Cosette Pharmaceuticals, Inc.
-
FDA approval · 2013-07-03FDA Approved: AZOR — Supplemental Application (Cosette Pharmaceuticals, Inc.)
FDA approved a supplemental application for AZOR (amlodipine besylate and olmesartan medoxomil) from Cosette Pharmaceuticals, Inc.
-
FDA approval · 2013-07-03FDA Approved: TRIBENZOR — Supplemental Application (Cosette Pharmaceuticals, Inc.)
The FDA approved a supplemental application for TRIBENZOR, the triple combination antihypertensive (olmesartan medoxomil/amlodipine besylate…